Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

StatusActive, Not Recruiting
PhasePhase 2
SponsorLiping Dou
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 12 months later Mar 31, 2026 → Mar 31, 2027
See other at-risk trials from Liping Dou

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Mar 31, 2026 to Mar 31, 2027
    • Start date: Mar 31, 2026 to Jul 30, 2026
    • Eligibility criteria expanded, about 21 words
  2. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Liping Dou
9 trials monitored
See 1 trial at risk
Leukemia
2,957 trials monitored
See 176 trials at risk
Acute Myeloid Leukemia (AML)
1,275 trials monitored
See 74 trials at risk
The purpose of this study is to determine the efficacy and safety of the Beach regimen on relapsed/refractory acute myeloid leukemia
Trial Details
NCT Number NCT07651475
Lead Sponsor Liping Dou
Conditions
(from sponsor)		 R/R AML
Enrollment 32 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov